A few interesting little things from Q1 Earnings...1. "Year-ending cash is expected to be above $10 million".
Versus "Year-ending cash is expected to reach $10M" (from q4)
2. an increase in business development consulting fees of
$125,000. Didn't see any significant fees for all of 2023
3.From the MDA- During the quarter ended October 31, 2023, research and development expenses totaled $122,232 compared to $150,415 in the same period year ago, mainly due to a decrease in consultants and in labor hours for the diamine oxidase (DiaMaze®) development program.